Etavopivat

A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
45 patients (estimated)
Sponsors
Forma Therapeutics, Inc.
Tags
Pyruvate Kinase (PKR)
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1620
NCT Identifier
NCT05568225

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.